EANS-Adhoc: Intercell AG announces Q3 2010 results and updates on R&D progress and management
ad-hoc disclosure transmitted by euro adhoc with the aim of a Europe-wide distribution. The issuer is solely responsible for the content of this announcement. 9-month report 09.11.2010 Positive sales trend of IXIARO®/JESPECT® vaccine against Japanese Encephalitis - Focused R&D spending on late-stage programs and negative currency effects lead to EUR ...